Lisata Therapeutics, Inc. (LSTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 6, 2025, by Lisata Therapeutics, Inc., a Delaware corporation. The filing serves to disclose the Company's financial results for the third quarter ended September 30, 2025, pursuant to Regulation FD.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1 and the corporate presentation furnished as Exhibit 99.2, which are incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. Investors must refer to the attached press release (Exhibit 99.1) for a comparison of the third quarter 2025 results against prior periods.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and risk factors are included in the press release and slide presentation attached as Exhibits 99.1 and 99.2. The 8-K explicitly states that the information in these exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other registration statements unless expressly stated.
Key Facts for Investor Verification
- Verify the specific Q3 2025 financial results (revenue, net loss, cash position) in the attached press release (Exhibit 99.1).
- Review the corporate presentation (Exhibit 99.2) for updated clinical trial timelines and operational milestones.
- Confirm the Company's cash runway and any recent financing activities mentioned in the exhibits.
- Note that the exhibits are furnished for informational purposes and carry different liability standards than "filed" documents.